

MERGENT INDUSTRIAL

NEW LISTING

January 19, 2010

This Supplemental News Reports is published as required, is part of the annual MERGENT INDUSTRIAL, OTC and OTC UNLISTED MANUALS and will be included in the bound 2010 January Monthly News Reports and is published on our Website.

INVO BIOSCIENCE, INC.

Company Website: www.invobioscience.com

History: Incorporated in Nevada on July 11, 2005 as Emy's Salsa Aji Distribution Company, Inc. a successor to Certiorari Corp. Present name adopted on Feb. 17, 2009.

On Dec. 5, 2008, Co. merged with BioXcell, Inc with BioXcell became a subsidiary of Co.

Business Summary: INVO Bioscience is engaged in the manufacture and sale of its CE Mark approved INVOcell device and the INVO technology to assist infertile couples in having baby.

Property: Co. maintains its principal executive office in a leased facility of 3,294 square feet in Beverly, MA.

Subsidiary

BioXcell, Inc.

Officers

Claude Ranoux, MD, President; Treasurer
Kathleen Karloff, Chief Executive Officer; Secretary
Robert J. Bowdring, Chief Financial Officer; Chief Accounting Officer; Corporate Controller

Directors

Kathleen Karloff
Claude Ranoux, MD

Auditors: RBSM LLP

Counsel: Shulman Rogers, Gandal, Pordy, and Ecker, P.A., Rockville, MD

Shareholder Relations: Katie Karloff, CEO Tel.: 978-878-9505 ext 504

No. of Stockholders: Dec. 31, 2009, 99

No. of Employees: Dec. 31, 2009, 5

Address: 100 Cummings Center, Suite 421E, Beverly, MA 01915 **Tel.:** 978 878-9505 ext 508 **Fax:** 978 878-9505 **E-mail:** rbowdring@invobio.com **Web:** www.invobioscience.com

Consolidated Income Account, years ended Dec. 31
(in \$):

	2008	2007
Prod rev	37,995	
Prod costs	10,088	
Gross margin	27,907	
Research & devel		
exps	51,761	33,350
Selling, gen & admin		
exps	1,837,606	177,170
Tot oper exps	1,889,367	210,520
Income (loss) fr		
opers	(1,861,460)	(210,520)
Int exp	11,945	3,569
Tot other exps	11,945	3,569
Income (loss) bef inc		
tax	(1,873,405)	(214,089)
Net income (loss)	(1,873,405)	(214,089)
Common shares :		
Weigh avg shares		
outstg-basic	36,691,176	24,649,031
Weigh avg shares		
outstg-diluted	36,691,176	24,649,031

Yr end shares outstg	53,620,000	
Net earnings (loss)		
per sh-basic	\$(0.05)	\$(0.01)
Net earnings (loss)		
per sh-diluted	\$(0.05)	\$(0.01)
From January 5, 2007 (Inception)		

Consolidated Balance Sheet, as of Dec. 31 (in \$):

	2008	2007
Assets:		
Cash	15,716	
Accts receiv	34,195	
Other receiv	7,500	
Work in process	55,466	
Finished goods	15,257	
Invent	70,722	
Ppd exps	73,785	3,349
Tot curr assets	201,918	3,349
Manufacturing		
equipment- Molds,		
gross	35,263	
Less: Accum		
deprec-Manufacturing	980	
Network/IT		
equipment, gross	7,595	
Less: Accum		
deprec-Network/IT	633	
equ		
Prop & equipment,		
net	41,245	
Defer financing costs,		
net	9,153	
Cap patents, net	68,392	43,270
Tot other assets	68,392	52,423
Tot assets	311,555	55,772
Liabilities:		
Accts pay	226,861	10,351
Accrued exps	614,799	3,581
Line of cr	50,000	49,221
Tot curr liabil	891,660	63,153
Note payable- rel		
party	96,462	93,545
Tot long term liabil	96,462	93,545
Tot liabil	988,122	156,698
Com stk	5,362	2,499
Addit paid-in cap	1,855,565	110,664
Stk subscription		
receiv	(450,000)	
(Accum deficit) retain		
earn during devel		
stage	(2,087,494)	(214,089)
Tot stkhlders equity	(676,567)	(100,926)
(deficiency)		
As reported by the Company		

Auditor's Report: The following is an excerpt from the Report of the Independent Auditors, RBSM LLP, as it appeared in the 2008 10K report:

"In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Invo Bioscience, Inc. a development stage company, at December 31, 2008 and the results of its operations and its cash flows for the year ended December 31, 2008 and for the period January 5, 2007 (date of inception) through December 31, 2008 in conformity with accounting principles generally accepted in the United States of America.

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2, the Company has a generated negative cash outflows from operating activities, experienced recurring net operating losses, and is dependent on securing additional equity and debt financing to support its business efforts. These factors raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regards to this matter are described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."

Long Term Debt: Dec. 31, 2008, \$96,462 (excluding current portion) non-convertible note payable-related party with interest rate of 5% due Mar. 31, 2010.

Line of Credit: At Dec. 31, 2008, the Company had a \$50,000 working capital line of credit with Century Bank, interest payable monthly 0.24% above the bank's prime lending rate on Dec. 31, 08 the rate was 3.79%, maturing May 31, 2010. At Dec. 31, 2008, the balance outstanding on the line of credit was \$50,000.

Capital: 1. INVO Bioscience, Inc. common; par \$0.0001.

AUTH — 200,000,000 shs.

OUTSTG — Dec. 31, 2008 53,620,000 shs; par \$0.0001.

OPTIONS — Dec. 31, 2008, outstanding, 140,000 shs.

ISSUED — (4,561,641 shares) from \$0.15 to \$1.50 per share from Jan. 1, 2008 through Nov. 30, 2008 (proceeds to Co., \$706,938).

(8,488,857 shares) in Mar. 2008 (proceeds to Co., \$11,259).

(265,623 shares) in Nov. 2008 (proceeds to Co., \$40,056).

(83,333 shares) in Mar. 2009 (proceeds to Co., \$37,500).

(125,000 shares) in May 2009 (proceeds to Co., \$15,500).

(857,000 shares) in Sept. 2009 (proceeds to Co., \$299,950).

TRANSFER AGENT — Island Stock Transfer Inc., St. Petersburg, FL

LISTED — Over-the-Counter (OTC): IVOB

MERGENT MANUALS (ISSN 0895-3252) is published weekly on Tuesday by Mergent 60 Madison Ave., New York, NY 10010. Subscription rate \$647.50 per annum for the News Report portion of the Mergent Manuals service in the United States and Canada (Not to be sold separately from the Manual). Copyright © 2008 by Mergent. All Information contained herein is copyrighted in the name of Mergent and none of such information may be copied or otherwise reproduced, repackaged, further transmitted, transferred, disseminated, redistributed or resold, or stored for subsequent use for any such purpose, in whole or in part, in any form or matter or by any means whatsoever, by any person without prior written consent.

All information contained herein is obtained by MERGENT, from sources believed by it to be accurate and reliable. Because of the possibility of human and mechanical error as well as other factors, however, such information is provided "as is" without warranty of any kind. NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY INFORMATION IS GIVEN OR MADE BY MERGENT IN ANY FORM OR MANNER WHATSOEVER. Under no circumstances shall MERGENT have any liability to any person or entity for (a) any loss or damage in whole or in part caused by, resulting from, or relating to, any error (negligent or otherwise) or other circumstance involved in procuring, collecting, compiling, interpreting, analyzing, editing, transcribing, transmitting, communicating or delivering any such information, or (b) any direct, indirect, special, consequential or incidental damages whatsoever, even if MERGENT is advised in advance of the possibility of such damages, resulting from the use of, or inability to use, any such information.